Scientists from the John Innes Centre have proven that by taking a short stretch of DNA from a bacterium and delivering it with an existing antibiotic they can switch off antibiotic resistance.
Together with technology transfer company PBL, the scientists have launched a spin-out company, Procarta Biosystems Ltd, to develop the technology.
“The DNA sequence acts as a decoy, disrupting gene expression and blocking resistance”, said Dr Michael McArthur from JIC.
“We are putting genetic information directly into drugs. This is the first application of a DNA based therapy”.
The scientists have also patented a way of discovering decoys in bacteria without necessarily having to know the genes involved. This means they can develop effective new drugs against any bacterium within a couple of years and at a fraction of the normal cost.
The technology can give fresh patent life to existing antibiotics - when combined with a decoy they can be patented as a new drug.
This comes at a time when the number of new antibiotics receiving approval has dramatically declined. Faced with antibiotic resistance the pharmaceutical industry is unlikely to be able to deliver new products.
“Natural resistance will always be hot on the heels of a new antibiotic because they co-evolve”, said Dr McArthur. “Ours’ is not a traditional pharmaceutical approach and provides a completely new challenge to bacteria”.
The technology can also be used to improve the production of antibiotics by bacteria and to produce enzymes and other compounds using bacteria for use in industrial processes.
Many industrial processes are harsh and unsustainable, using petrochemicals, high temperatures and creating toxic by-products. In industrial biotechnology, also called “white biotechnology”, bacteria make medically and commercially important compounds biologically.
“By using bacteria, many industrial processes could be cleaned up”, said Dr McArthur.
The Procarta scientists found that the bacterium Streptomyces produces a particularly high yield of enzymes and proteins. Unusually, it can also secrete the proteins it produces so they do not have to be extracted.
“Streptomyces is the enzyme producing bacterium with bells and whistles, set to make a major contribution to a market already predicted to be worth £400 million by 2010”, said Dr McArthur.
We use the products of white biotechnology in our everyday lives. They contribute to ingredients in the food we eat, energy we use that has been generated with renewable biomass rather than fossil fuels, medicines we take, and everyday products such as detergents, paint and paper.
Source: Norwich BioScience Institutes
Related stories:
New antibiotic beats superbugs at their own game
The problem with antibiotics is that, eventually, bacteria outsmart them and become resistant. But by targeting the gene that confers such resistance, a new drug may be able to finally outwit them. Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.
Being an MRSA carrier increases risk of infection and death
Patients harboring methicillin-resistant Staphylococcus aureus (MRSA) for long periods of time continue to be at increased risk of MRSA infection and death, according to a new study in the July 15 issue of
Clinical Infectious Diseases, currently available online.
TB Treatment For The Elderly Likely Requires A Boost To Immune Response
Manipulating the immune system in elderly people appears to be the most likely way to help older patients wage an effective battle against tuberculosis, a new study suggests.
Salmonella in garden birds responsive to antibiotics
Scientists at the University of Liverpool have found that Salmonella bacteria found in garden birds are sensitive to antibiotics, suggesting that the infection is unlike the bacteria found in livestock and humans.
Potential treatments from cryptic genes
Big pharma gave up on soil bacteria as a source of antibiotics too soon, according to research published in the June issue of
Microbiology. Scientists have been mining microbial genomes for new natural products that may have applications in the treatment of MRSA and cancer and have made some exciting discoveries.
Researchers bring new meaning to the term 'computer bug'
US researchers have created ‘living computers’ by genetically altering bacteria. The findings of the research, published in BioMed Central’s open access
Journal of Biological Engineering, demonstrate that computing in living cells is feasible, opening the door to a number of applications including data storage and as a tool for manipulating genes for genetic engineering.
An ancient protein balances gene activity and silences foreign DNA in bacteria
Compared to humans, bacteria have a much tidier genome. The tiny microorganisms pack their genes closely together, and don’t carry around a lot of extraneous DNA, so-called junk DNA that fills in the gaps between genes. Some 90 percent of the complete genome sequence of the bacteria E. coli contains sequences of DNA that code for protein, while 90 percent of the human genome is non–coding junk DNA.
Scientists discover how some bacteria survive antibiotics
Researchers at the University of Illinois at Chicago have discovered how some bacteria can survive antibiotic treatment by turning on resistance mechanisms when exposed to the drugs. The findings, published in the April 24 issue of the journal
Molecular Cell, could lead to more effective antibiotics to treat a variety of infections.